

Tabel 5. Medicamenten waarvan met een lage bewijskracht is gerapporteerd dat zij xerostomie, hypofunctie van de speekselklieren of sialorrhoea kunnen veroorzaken.

* = Niet vermeld in het farmacotherapeutisch kompas.

Medicament*	Aantal citaties voor:				Aantal bronnen per niveau van bewijskracht		Total aantal publicaties	Referentie(s)
	Monddroogheid		Monddroogheid		A3	B3		
	Xerostomie	Hypofunctie	Subjectief	Objectief				
amiloride	0	1	0	0	1	0	1	1
apraclonidine	1	0	0	0	0	1	1	2
asimadoline*	1	0	0	0	0	1	1	3
atomoxetine	1	0	0	0	0	1	1	4
biperiden	1	1	0	0	1	0	1	1
chlorpheniramine*	1	0	0	0	0	1	1	5
chloorprotixeen	0	1	0	0	1	0	1	1
cisplatina	1	0	0	0	0	1	1	6
clomipramine	3	0	0	0	0	3	3	7-9
cyclothiazide*	0	1	0	0	1	0	1	1
cytisine	1	0	0	0	0	1	1	10
diltiazem	0	1	0	0	1	0	1	1
dimenhydrinate*	2	0	0	0	0	2	2	5, 11
diphenhydramine*	1	0	0	0	0	1	1	5
disopyramide	1	0	0	0	1	0	1	1
flupirtine*	1	0	0	0	0	1	1	12
granisetron	1	0	0	0	0	1	1	13
guanfacine	2	0	0	0	0	2	2	14, 15
interleukine-2a	0	1	0	0	1	0	1	1
ipratropium	1	0	0	0	0	1	1	16
levomepromazine	0	1	0	0	1	0	1	1
maprotiline	1	1	0	0	1	0	1	1
mazindol*	1	0	0	0	0	1	1	17
melperone*	0	1	0	0	1	0	1	1
mepyramine*	1	0	0	0	0	1	1	5
metiamide*	0	1	0	0	1	0	1	1
milnacipran*	3	0	0	0	0	3	3	18-20
mirtazapine	2	0	0	0	0	2	2	21, 22
moclobemide	1	0	0	0	0	1	1	23
modafinil	2	0	0	0	0	2	2	7, 24
mosapride*	1	0	0	0	0	1	1	25
moxifloxacin	1	0	0	0	0	1	1	26
moxonidine	3	0	0	0	0	3	3	14, 27, 28
nefazodone*	2	0	0	0	0	2	2	29, 30
oxitropium	1	0	0	0	0	1	1	16
perindopril	1	0	0	0	0	1	1	31
pethidine	0	1	0	0	1	0	1	1
fenelzine	1	0	0	0	0	1	1	32
Pheniramine*	0	1	0	0	0	1	1	5
promazine	1	0	0	0	0	1	1	33
protriptyline	2	0	0	0	0	2	2	7, 17
pseudoephedrine	1	0	0	0	0	1	1	34
rilmenidine*	2	0	0	0	0	2	2	14, 26
selegiline	1	1	0	0	1	1	2	1, 23
thioridazine*	2	1	0	0	1	0	1	1
tianeptine*	1	0	0	0	1	0	1	35
triptoreline	1	0	0	0	0	1	1	5
zimeldine*	0	1	0	0	1	0	1	1

Literatuur

1. Narhi TO, Meurman JH, Ainamo A. Xerostomia and hyposalivation: causes, consequences and treatment in the elderly. *Drugs Aging*. 1999;15:103-16.
2. Diamond JP. Systemic adverse effects of topical ophthalmic agents. Implications for older patients. *Drugs Aging*. 1997;11:352-60.
3. Mangel AW, Hicks GA. Asimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: A review. *Clin Exp Gastroenterol*. 2012;5:1-10.
4. Simpson D, Plosker GL. Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. *Drugs*. 2004;64:205-22.
5. Bouwer A. Combination cold and flu medicines: An overview of autonomic nervous system receptors. *SAfrican Fam Pract*. 2012;54:33-6.
6. Boven E, Westerman M, van Groeningen CJ, Verschraagen M, Ruijter R, et al. Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule. *Br J Cancer*. 2005;92:1636-43.
7. Bhat A, El Solh AA. Management of narcolepsy. *Exp Opin Pharmacotherapy*. 2008;9:1721-33.
8. Kendirci M, Salem E, Hellstrom WJG. Dapoxetine, a novel selective serotonin transport inhibitor for the treatment of premature ejaculation. *Ther Clin Risk Manag*. 2007;3:277-89.
9. Kodish I, Rockhill C, Varley C. Pharmacotherapy for anxiety disorders in children and adolescents. *Dialogues Clin Neurosci*. 2011;13:439-52.
10. Tutka P, Zatonski W. Cytisine for the treatment of nicotine addiction: From a molecule to therapeutic efficacy. *Pharmacol Rep*. 2006;58:777-98.
11. Finlay E, Straton JB, Gavrin JR. Nausea and vomiting: An overview of mechanisms and treatment in older patients. *Geriatrics and Aging*. 2007;10:116-21.
12. Friedel HA, Fitton A. Flupirtine. A review of its pharmacological properties, and therapeutic efficacy in pain states. *Drugs*. 1993;45:548-69.
13. Moreno J, Sahade M, del Giglio A. Low-dose granisetron for prophylaxis of acute chemotherapy-induced nausea and vomiting: a pilot study. *Support Care Cancer*. 2005;13:850-3.
14. van Zwieten PA. Centrally acting antihypertensives: a renaissance of interest. Mechanisms and haemodynamics. *J Hypertens Suppl*. 1997;15:S3-8.
15. Vongpatanasin W, Kario K, Atlas SA, Victor RG. Central sympatholytic drugs. *J Clin Hypertens (Greenwich)*. 2011;13:658-61.
16. Newnham DM. Asthma medications and their potential adverse effects in the elderly: Recommendations for prescribing. *Drug Safety*. 2001;24:1065-80.
17. Billiard M. Narcolepsy: Current treatment options and future approaches. *Neuropsych Dis Treatment*. 2008;4:557-66.
18. Serretti A, Chiesa A, Calati R, Perna G, Bellodi L, De Ronchi D. Novel antidepressants and panic disorder: Evidence beyond current guidelines. *Neuropsychobiol*. 2010;63:1-7.
19. Ormseth MJ, Eyler AE, Hammonds CL, Boomershine CS. Milnacipran for the management of fibromyalgia syndrome. *J Pain Res*. 2010;3:15-24.
20. Blaya C, Seganfredo AC, Dornelles M, Torres M, Paludo A, Heldt E. et al. The efficacy of milnacipran in panic disorder: An open trial. *Int Clin Psychopharmacol*. 2007;22:153-8.
21. Montgomery SA. Safety of mirtazapine: a review. *Int Clin Psychopharmacol*. 1995;10 Suppl 4:37-45.
22. Coskun M, Ahmetoglu E, Ozturk M. Mirtazapine treatment for comorbid anxiety/depressive disorders in young subjects with attention-deficit hyperactivity disorder: Case series. *Klinik Psikofarmakoloji Bulteni*. 2010;20:246-51.
23. Volz HP, Gleiter CH. Monoamine oxidase inhibitors. A perspective on their use in the elderly. *Drugs Aging*. 1998;13:341-55.
24. Schwartz JRL. Modafinil in the treatment of excessive sleepiness. *Drug Design Develop Ther*. 2008;2:71-85.
25. Curran MP, Robinson DM. Mosapride in gastrointestinal disorders. *Drugs*. 2008;68:981-91.
26. Tulkens PM, Arvis P, Kruesmann F. Moxifloxacin safety: An analysis of 14 years of clinical data. *Drugs in R and D*. 2012;12:71-100.
27. Webster J, Koch HF. Aspects of tolerability of centrally acting antihypertensive drugs. *J Cardiovasc Pharmacol*. 1996;27: Suppl 3, S49-S54.
28. Prichard BN, Graham BR. II imidazoline agonists. General clinical pharmacology of imidazoline receptors: implications for the treatment of the elderly. *Drugs Aging*. 2000;17:133-59.
29. Ellingrod VL, Perry PJ. Nefazodone: a new antidepressant. *Am J Health Syst Pharm*. 1995;52:2799-812.
30. Davis R, Whittington R, Bryson HM. Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. *Drugs*. 1997;53:608-36.
31. West D, Chambers S. Drug review - Perindopril. *Drugs in Context*. 2006;2:17-34.
32. Johnsen E, Jorgensen HA. Effectiveness of second generation antipsychotics: A systematic review of randomized trials. *BMC Psychiatry*. 2008;8:1-14.
33. Gareri P, De Fazio P, De Fazio S, Marigliano N, Ferreri Ibbadu G, De Sarro G. Adverse effects of atypical antipsychotics in the elderly: a review. *Drugs Aging*. 2006;23:937-56.
34. Wellington K, Jarvis B. Cetirizine/pseudoephedrine. *Drugs*. 2001;61:2231-2240; discussion 2241-2232.
35. Wilde MI, Benfield P. Tianeptine - a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depression and coexisting anxiety and depression. *Drugs*. 1995;49:411-39.